Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has further increased its production of Tauri-Gum™ inventory to support its ongoing commercial launch. In total, the Company has placed orders with its manufacturer for an additional 17,400 blister packs (“packs” or “units”) of Tauri-Gum™, on top of the 8,700 units that comprise the initial inventory tranche (“initial production run”). The Company has continued to augment its inventory production, in response to what it believes to be, increasingly strong levels of interest from prospective distributors, retailers, and customers. The Company is working with great diligence to gain market share for its CBD Infused gum (“Tauri-Gum™”) and is encouraged by the feedback it has received at a number of important recent meetings.
To date, inclusive of both the March 7, 2019 and March 12, 2019 inventory re-orders, the Company has placed in aggregate; orders with its manufacturer for 26,100 Tauri-Gum™ units.
In other news, the Company has increased its Research and Development (“R & D”) budget with the manufacturer and is currently in the process of testing new flavors as well as other product enhancements. The Company has engaged its graphic artist to implement package design modifications to correlate with these potential new flavor(s).
ABOUT: TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-GumTM . See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com.
In addition, the Company is currently constructing an E-Commerce site for the sale of its CBD Infused Chewing Gum. This site is being constructed under the following URL address: www.taurigum.com
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
cell # (917) 796 9926